RxDoctor Payments Data

Zaheer Aslam, MD

Addiction Psychiatry · Fort Myers, FLNPI 1609950468

Payments from drug & device makers

What this record shows

Merck accounts for 76.6% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $1,086 and has fallen 96.7% since, to $36 in 2025.

$1,352in general payments, 2019–2025

Across 24 payments — averaging $56.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1K
  • Alkermes, Inc.$84
  • Johnson & Johnson$51
  • Braeburn Inc.$38
  • Almatica Pharma LLC$31
  • Otsuka America Pharmaceutical, Inc.$24
  • plus $88 from 5 others
$2,042,055in research payments, 2019–2025

Across 365 payments — averaging $5594.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$468K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$372K
  • Supernus Pharmaceuticals, Inc.$273K
  • Boehringer Ingelheim$198K
  • Arbor Pharmaceuticals, Inc.$171K
  • AbbVie$162K
  • plus $398K from 10 others

What the payments were for

  • Travel & lodging$77958%
  • Food & beverage$57442%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,352 in reported general payments places this provider in the 65th percentile of 29 addiction psychiatry providers in Florida.

See all addiction psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$37,523
Medicare patients
15
Services billed
409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine11$62,639
SpravatoEsketamine Hcl25$35,230
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl154$22,607
ZubsolvBuprenorphine Hcl/Naloxone Hcl27$22,370
Seroquel XrQuetiapine Fumarate13$18,733
RexultiBrexpiprazole12$18,655
VraylarCariprazine Hcl12$17,292
AuvelityDextromethorphan Hbr/Bupropion16$15,896
Aripiprazole134$6,924
VyvanseLisdexamfetamine Dimesylate19$6,797
Quetiapine Fumarate160$2,818
Bupropion XlBupropion Hcl174$2,750
SeroquelQuetiapine Fumarate12$2,310
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine41$2,023
Ziprasidone Hcl31$1,759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$51$35,23025 claims
Otsuka America Pharmaceutical, Inc.Rexulti$24$18,65512 claims
AbbVieVraylar$18$17,29212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 29 addiction psychiatry providers in Florida.

Other addiction psychiatry in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →